In July 2021, Nebion AG, the company developing GENEVESTIGATOR^®, was acquired by Immunai Inc., a biotech company focusing on developing immunomodulatory drugs using a combination of single-cell multiomics technologies with machine learning. As previously announced, GENEVESTIGATOR^® Plants was phased out by December 31 2023.